Well, I’ve certainly heard from a number of people regarding my earlier post onĀ  the compulsory license granted by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of Bayer’s drug Sorafenib Tosylate (Nexavar), a drug used to treat liver and kidney cancer. The gist of the complaints are that I’m […]